Nicole C Ammerman

List of Publications by Year
in descending order

49 papers	2,871 citations	172457 29 h-index	197818 49 g-index
54 all docs	54 docs citations	54 times ranked	3798 citing authors

#	Article	IF	Citations
1	Targeting DnaN for tuberculosis therapy using novel griselimycins. Science, 2015, 348, 1106-1112.	12.6	262
2	Plasmids and Rickettsial Evolution: Insight from Rickettsia felis. PLoS ONE, 2007, 2, e266.	2.5	212
3	Growth and Maintenance of Vero Cell Lines. Current Protocols in Microbiology, 2008, 11, Appendix 4E.	6.5	167
4	Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 600-607.	5.6	149
5	Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nature Communications, 2013, 4, 2907.	12.8	130
6	Preliminary Structureâ€"Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains. Journal of Medicinal Chemistry, 2013, 56, 4093-4103.	6.4	118
7	Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 869-874.	7.1	116
8	Non-classical transpeptidases yield insight into new antibacterials. Nature Chemical Biology, 2017, 13, 54-61.	8.0	116
9	Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 608-612.	5.6	114
10	Pharmacokinetics and Pharmacodynamics of Clofazimine in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 3042-3051.	3.2	93
11	An Anomalous Type IV Secretion System in Rickettsia Is Evolutionarily Conserved. PLoS ONE, 2009, 4, e4833.	2.5	89
12	<i>Mycobacterium tuberculosis</i> dysregulates <scp>MMP</scp>/<scp>TIMP</scp> balance to drive rapid cavitation and unrestrained bacterial proliferation. Journal of Pathology, 2015, 235, 431-444.	4.5	86
13	<i>In Vitro</i> Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of <i>Mycobacterium abscessus</i>. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	84
14	Laboratory Maintenance of <i>Rickettsia rickettsii</i>. Current Protocols in Microbiology, 2008, 11, Unit 3A.5.	6.5	73
15	Spotted-Fever Group<i>Rickettsia</i>in<i>Dermacentor variabilis</i>, Maryland. Emerging Infectious Diseases, 2004, 10, 1478-1481.	4.3	65
16	Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model. PLoS ONE, 2012, 7, e30749.	2.5	61
17	Gene Expression of Mycobacterium tuberculosis Putative Transcription Factors whiB1-7 in Redox Environments. PLoS ONE, 2012, 7, e37516.	2.5	60
18	Surface Proteome Analysis and Characterization of Surface Cell Antigen (Sca) or Autotransporter Family of Rickettsia typhi. PLoS Pathogens, 2012, 8, e1002856.	4.7	57

#	Article	IF	Citations
19	Functional Characterization of a Phospholipase A ₂ Homolog from <i>Rickettsia typhi</i>. Journal of Bacteriology, 2010, 192, 3294-3303.	2.2	55
20	Louse- and flea-borne rickettsioses: biological and genomic analyses. Veterinary Research, 2009, 40, 12.	3.0	52
21	TolC-Dependent Secretion of an Ankyrin Repeat-Containing Protein of Rickettsia typhi. Journal of Bacteriology, 2012, 194, 4920-4932.	2.2	51
22	Adjuvant Host-Directed Therapy with Types 3 and 5 but Not Type 4 Phosphodiesterase Inhibitors Shortens the Duration of Tuberculosis Treatment. Journal of Infectious Diseases, 2013, 208, 512-519.	4.0	46
23	<i>In Vitro</i> Activity of the New Î²-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with Î²-Lactams against Mycobacterium abscessus Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	45
24	Clofazimine has delayed antimicrobial activity against<i>Mycobacterium tuberculosis</i>both<i>in vitro</i>and<i>in vivo</i>. Journal of Antimicrobial Chemotherapy, 2017, 72, 455-461.	3.0	44
25	Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis. Nature Communications, 2012, 3, 753.	12.8	40
26	Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations. Antimicrobial Agents and Chemotherapy, 2015, 59, 2129-2135.	3.2	40
27	Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	37
28	Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	36
29	Molecular Differentiation of Metastriate Tick Immatures. Vector-Borne and Zoonotic Diseases, 2004, 4, 334-342.	1.5	34
30	Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15001-15005.	7.1	33
31	Rv2190c, an NlpC/P60 Family Protein, Is Required for Full Virulence of Mycobacterium tuberculosis. PLoS ONE, 2012, 7, e43429.	2.5	30
32	In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2320-2325.	3.0	30
33	Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 2864-2869.	3.2	28
34	Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis. Journal of Infectious Diseases, 2016, 213, 618-627.	4.0	27
35	Characterization of Sec-Translocon-Dependent Extracytoplasmic Proteins of Rickettsia typhi. Journal of Bacteriology, 2008, 190, 6234-6242.	2.2	26
36	Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. PLoS Neglected Tropical Diseases, 2018, 12, e0006728.	3.0	26

#	Article	IF	Citations
37	Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 659-665.	3.0	25
38	Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
39	A Typhus Group-Specific Protease Defies Reductive Evolution in Rickettsiae. Journal of Bacteriology, 2009, 191, 7609-7613.	2.2	17
40	New Î²-Lactamase Inhibitors Nacubactam and Zidebactam Improve the <i>In Vitro</i> Activity of Î²-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
41	Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice. Mycobacterial Diseases: Tuberculosis & Leprosy, 2014, 04, 145.	0.1	11
42	Differential <i>In Vitro</i> Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	11
43	Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 570-579.	5.6	10
44	Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0170521.	3.2	5
45	Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0179321.	3.2	5
46	<i>In Vitro</i> Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0154521.	3.2	4
47	An Adaptive Biosystems Engineering Approach towards Modeling the Soluble-to-Insoluble Phase Transition of Clofazimine. Pharmaceutics, 2022, 14, 17.	4.5	4
48	Quantitative Analysis of the Phase Transition Mechanism Underpinning the Systemic Self-Assembly of a Mechanopharmaceutical Device. Pharmaceutics, 2022, 14, 15.	4.5	4
49	Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207). Expert Review of Anti-Infective Therapy, 2013, 11, 649-651.	4.4	3